146 related articles for article (PubMed ID: 38833177)
1. Enhanced abscopal anti-tumor response via a triple combination of thermal ablation, IL-21, and PD-1 inhibition therapy.
Wu S; Jiang H; Fang Z; Wu Y; Jiao J; Fang W; Wu Y; Lang Y; Chen N; Zhong Z; Chen L; Zheng X; Lu B; Jiang J
Cancer Immunol Immunother; 2024 Jun; 73(8):138. PubMed ID: 38833177
[TBL] [Abstract][Full Text] [Related]
2. LAG3 blockade coordinates with microwave ablation to promote CD8
Shao D; Chen Y; Huang H; Liu Y; Chen J; Zhu D; Zheng X; Chen L; Jiang J
J Transl Med; 2022 Sep; 20(1):433. PubMed ID: 36180876
[TBL] [Abstract][Full Text] [Related]
3. TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation Against Cancer.
Chen Y; Huang H; Li Y; Xiao W; Liu Y; Chen R; Zhu Y; Zheng X; Wu C; Chen L
Front Immunol; 2022; 13():832230. PubMed ID: 35320940
[TBL] [Abstract][Full Text] [Related]
4. Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice.
Duan X; Wang M; Han X; Ren J; Huang G; Ju S; Zhang Q
Cell Cycle; 2020 Dec; 19(24):3595-3607. PubMed ID: 33283623
[TBL] [Abstract][Full Text] [Related]
5. CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor.
Chen JS; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
Sci Rep; 2022 Jan; 12(1):1100. PubMed ID: 35058524
[TBL] [Abstract][Full Text] [Related]
6. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
7. PD-1 blockade-unresponsive human tumor-infiltrating CD8
Kim KH; Kim HK; Kim HD; Kim CG; Lee H; Han JW; Choi SJ; Jeong S; Jeon M; Kim H; Koh J; Ku BM; Park SH; Ahn MJ; Shin EC
Cell Mol Immunol; 2021 Feb; 18(2):385-397. PubMed ID: 32332901
[TBL] [Abstract][Full Text] [Related]
8. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
9. A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.
Ma HS; Poudel B; Torres ER; Sidhom JW; Robinson TM; Christmas B; Scott B; Cruz K; Woolman S; Wall VZ; Armstrong T; Jaffee EM
Cancer Immunol Res; 2019 Mar; 7(3):428-442. PubMed ID: 30642833
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
[TBL] [Abstract][Full Text] [Related]
11. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
[TBL] [Abstract][Full Text] [Related]
12. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8
Zou Z; Shen J; Xue D; Li H; Xu L; Cao W; Wang W; Fu YX; Peng H
Nat Commun; 2024 Jun; 15(1):4701. PubMed ID: 38830882
[TBL] [Abstract][Full Text] [Related]
14. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020
[TBL] [Abstract][Full Text] [Related]
15. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
16. Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers.
Kaneko K; Acharya CR; Nagata H; Yang X; Hartman ZC; Hobeika A; Hughes PF; Haystead TAJ; Morse MA; Lyerly HK; Osada T
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171008
[TBL] [Abstract][Full Text] [Related]
17. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
[TBL] [Abstract][Full Text] [Related]
18. Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.
Rodriguez-Ruiz ME; Rodriguez I; Garasa S; Barbes B; Solorzano JL; Perez-Gracia JL; Labiano S; Sanmamed MF; Azpilikueta A; Bolaños E; Sanchez-Paulete AR; Aznar MA; Rouzaut A; Schalper KA; Jure-Kunkel M; Melero I
Cancer Res; 2016 Oct; 76(20):5994-6005. PubMed ID: 27550452
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
20. Rocaglamide promotes infiltration and differentiation of T cells and coordinates with PD-1 inhibitor to overcome checkpoint resistance in multiple tumor models.
Luo J; Ng W; Liu Y; Wang L; Gong C; Zhou Y; Fang C; Zhu S; Yao C
Cancer Immunol Immunother; 2024 Jun; 73(8):137. PubMed ID: 38833034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
